AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 33892154 — intervention group
Group type: EXPERIMENTAL
Intervention: Eurythmy therapy
Number of subjects: 274
Study 33892154 — intervention group
Group type: COMPARATOR
Intervention: Standard physiotherapy
Number of subjects: 274
Study 34865452 — intervention group
Group type: EXPERIMENTAL
Intervention: rb‐bFGF gel
Number of subjects: 100
Study 34865452 — intervention group
Group type: COMPARATOR
Intervention: gel matrix
Number of subjects: 100
Study 34717154 — intervention group
Group type: EXPERIMENTAL
Intervention: IRX-2 regimen (low dose 300 mg/m2 cyclophosphamide on day 1, followed by 10 days of regional perilymphatic IRX-2 cytokine injections and daily oral indomethacin, zinc, and omeprazole)
Number of subjects: 0
Study 34717154 — intervention group
Group type: COMPARATOR
Intervention: Identical regimen without IRX-2 cytokines (Regimen 2)
Number of subjects: 0
Study 34717154 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison between Regimen 1 and Regimen 2
Number of subjects: 0
Study 34717154 — intervention group
Group type: EXPERIMENTAL
Intervention: Both regimens
Number of subjects: 0
Study 32240141 — intervention group
Group type: EXPERIMENTAL
Intervention: New technique of carotid endarterectomy (autoarterial remodeling)
Number of subjects: 25
Study 32240141 — intervention group
Group type: COMPARATOR
Intervention: Classical carotid endarterectomy
Number of subjects: 25
Study 35927828 — intervention group
Group type: EXPERIMENTAL
Intervention: Acacia honey
Number of subjects: 161
Study 35927828 — intervention group
Group type: COMPARATOR
Intervention: Honey-flavoured syrup placebo
Number of subjects: 161
Study 33653284 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-day bismuth-containing quadruple therapy (BQT)
Number of subjects: 352
Study 33653284 — intervention group
Group type: COMPARATOR
Intervention: 7-day proton-pump inhibitor-clarithromycin containing standard triple therapy (STT)
Number of subjects: 352
Study 36434615 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral nutritional supplements (ONS) with a high-protein-high calorie mixture containing immunonutrients (Impact®) plus nutritional counseling
Number of subjects: 180
Study 36434615 — intervention group
Group type: COMPARATOR
Intervention: Nutritional counseling alone
Number of subjects: 180
Study 34521385 — intervention group
Group type: EXPERIMENTAL
Intervention: Nomogram prediction model
Number of subjects: 463
Study 32636985 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent pneumatic compression plus standard compression therapy
Number of subjects: 52
Study 32636985 — intervention group
Group type: COMPARATOR
Intervention: Control (compression therapy alone)
Number of subjects: 52
Study 34347947 — intervention group
Group type: EXPERIMENTAL
Intervention: Mepolizumab 100 mg every 4 weeks
Number of subjects: 203
Study 34347947 — intervention group
Group type: EXPERIMENTAL
Intervention: Mepolizumab 300 mg every 4 weeks
Number of subjects: 203
Study 34347947 — intervention group
Group type: EXPERIMENTAL
Intervention: Mepolizumab (both doses)
Number of subjects: 203
Study 32748494 — intervention group
Group type: COMPARATOR
Intervention: Low systolic blood pressure (SBP)
Number of subjects: 412
Study 32748494 — intervention group
Group type: COMPARATOR
Intervention: Antihypertensive medication
Number of subjects: 412
Study 32748494 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous SBP levels
Number of subjects: 412
Study 33258784 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-centered asthma management communication intervention facilitated by a smartphone-based mobile app with a Spanish-language interface.
Number of subjects: 0
Study 33258784 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-centered asthma intervention from Aim 2.
Number of subjects: 0
Study 33258784 — intervention group
Group type: COMPARATOR
Intervention: Waiting-list control group (not explicitly detailed in the abstract).
Number of subjects: 0
Study 35100786 — intervention group
Group type: EXPERIMENTAL
Intervention: Leader assigned (n = 14)
Number of subjects: 92
Study 35100786 — intervention group
Group type: COMPARATOR
Intervention: Control (n = 11)
Number of subjects: 92
Study 35100786 — intervention group
Group type: EXPERIMENTAL
Intervention: Leader assigned teams (n = 14)
Number of subjects: 92
Study 35100786 — intervention group
Group type: COMPARATOR
Intervention: Control teams (n = 11)
Number of subjects: 92
Study 32877266 — intervention group
Group type: EXPERIMENTAL
Intervention: HTS Amblyopia I Net software (Amb I Net) using MFBF principle (2.5 hours per week)
Number of subjects: 54
Study 32877266 — intervention group
Group type: COMPARATOR
Intervention: Patching therapy (14–42 hours per week)
Number of subjects: 54
Study 33573674 — intervention group
Group type: EXPERIMENTAL
Intervention: MATCH-ADTC (modular psychological intervention) plus usual care
Number of subjects: 334
Study 33573674 — intervention group
Group type: COMPARATOR
Intervention: Assessment-enhanced usual care
Number of subjects: 334
Study 33573674 — intervention group
Group type: EXPERIMENTAL
Intervention: MATCH-ADTC plus usual care
Number of subjects: 334
Study 35963274 — intervention group
Group type: EXPERIMENTAL
Intervention: NVX-CoV2373 (5 μg SARS-CoV-2 rS with 50 μg Matrix-M adjuvant)
Number of subjects: 379
Study 35963274 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 379
Study 33144221 — intervention group
Group type: EXPERIMENTAL
Intervention: [11C]raclopride
Number of subjects: 16
Study 33144221 — intervention group
Group type: EXPERIMENTAL
Intervention: [11C]FLB 457
Number of subjects: 16
Study 34851810 — intervention group
Group type: EXPERIMENTAL
Intervention: Ten-session group intervention
Number of subjects: 28
Study 34851810 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 28
Study 34461058 — intervention group
Group type: EXPERIMENTAL
Intervention: Nocturnal oxygen therapy (Oxygen, n = 26)
Number of subjects: 52
Study 34461058 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP (n = 40)
Number of subjects: 52
Study 34461058 — intervention group
Group type: COMPARATOR
Intervention: No treatment (Air; n = 26)
Number of subjects: 52
Study 34264775 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based intervention
Number of subjects: 108
Study 32935460 — intervention group
Group type: EXPERIMENTAL
Intervention: Solriamfetol 300 mg
Number of subjects: 55
Study 32935460 — intervention group
Group type: EXPERIMENTAL
Intervention: Solriamfetol 900 mg
Number of subjects: 55
Study 32935460 — intervention group
Group type: COMPARATOR
Intervention: Moxifloxacin 400 mg
Number of subjects: 55
Study 32935460 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study 32719868 — intervention group
Group type: EXPERIMENTAL
Intervention: Vadadustat 150 mg
Number of subjects: 111
Study 32719868 — intervention group
Group type: EXPERIMENTAL
Intervention: Vadadustat 300 mg
Number of subjects: 111
Study 32719868 — intervention group
Group type: EXPERIMENTAL
Intervention: Vadadustat 600 mg
Number of subjects: 111
Study 32719868 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 111
Study 32719868 — intervention group
Group type: EXPERIMENTAL
Intervention: Vadadustat (all doses)
Number of subjects: 111
Study 35979054 — intervention group
Group type: EXPERIMENTAL
Intervention: Esketamine (0.5 mg/kg + 2 ml normal saline)
Number of subjects: 138
Study 35979054 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (2 ml)
Number of subjects: 138
Study 34171091 — intervention group
Group type: EXPERIMENTAL
Intervention: Type II diabetes mellitus (T2D)
Number of subjects: 898130
Study 34171091 — intervention group
Group type: EXPERIMENTAL
Intervention: T2D as a mediator
Number of subjects: 898130
Study 32920242 — intervention group
Group type: EXPERIMENTAL
Intervention: High intensity surveillance (Fukuoka guidelines)
Number of subjects: 4606
Study 32920242 — intervention group
Group type: COMPARATOR
Intervention: Low intensity surveillance (AGA guidelines)
Number of subjects: 4606
Study 34427295 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Number of subjects: 17134
Study 35022058 — intervention group
Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy (ACT) combined with routine nursing
Number of subjects: 98
Study 35022058 — intervention group
Group type: COMPARATOR
Intervention: Routine nursing (Control)
Number of subjects: 98
Study 32725529 — intervention group
Group type: EXPERIMENTAL
Intervention: Free-range group (shoulder range exercises until limited by pain or wound dehiscence)
Number of subjects: 60
Study 32725529 — intervention group
Group type: COMPARATOR
Intervention: Limited-range group (shoulder movement restriction at 90° until 30 days after surgery)
Number of subjects: 60
Study 35443830 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg dose of the COMT inhibitor tolcapone
Number of subjects: 74
Study 35443830 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 74
Study 33743059 — intervention group
Group type: EXPERIMENTAL
Intervention: Robot-assisted radical prostatectomy (RALP)
Number of subjects: 2650
Study 33743059 — intervention group
Group type: COMPARATOR
Intervention: Open retropubic radical prostatectomy (RRP)
Number of subjects: 2650
Study 32474206 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban 20 mg once daily
Number of subjects: 4500
Study 32474206 — intervention group
Group type: COMPARATOR
Intervention: Vitamin K antagonists (VKA)
Number of subjects: 4500
Study 35811435 — intervention group
Group type: COMPARATOR
Intervention: Guided bone regeneration (GBR) using a 1:1 mixture of particulate autogenous bone and anorganic bovine bone mineral (ABBM) covered with native collagen membrane
Number of subjects: 28
Study 35811435 — intervention group
Group type: EXPERIMENTAL
Intervention: Sticky bone using autologous fibrin glue (AFG) mixed with particulate autogenous bone and ABBM covered by concentrated growth factor (CGF) membrane
Number of subjects: 28
Study 32892660 — intervention group
Group type: EXPERIMENTAL
Intervention: Patisiran
Number of subjects: 0
Study 32892660 — intervention group
Group type: COMPARATOR
Intervention: Inotersen
Number of subjects: 0
Study 34626573 — intervention group
Group type: EXPERIMENTAL
Intervention: Monthly ranibizumab
Number of subjects: 605
Study 34626573 — intervention group
Group type: EXPERIMENTAL
Intervention: As-needed ranibizumab
Number of subjects: 605
Study 34626573 — intervention group
Group type: EXPERIMENTAL
Intervention: Monthly bevacizumab
Number of subjects: 605
Study 34626573 — intervention group
Group type: EXPERIMENTAL
Intervention: As-needed bevacizumab
Number of subjects: 605
Study 34626573 — intervention group
Group type: COMPARATOR
Intervention: Control group (no SMH)
Number of subjects: 605
Study 34193179 — intervention group
Group type: EXPERIMENTAL
Intervention: Real non-invasive brain stimulation (NIBS; real tDCS + iTBS)
Number of subjects: 24
Study 34193179 — intervention group
Group type: COMPARATOR
Intervention: Sham non-invasive brain stimulation (NIBS; sham tDCS + iTBS)
Number of subjects: 24
Study 36422763 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy
Number of subjects: 329
Study 36422763 — intervention group
Group type: COMPARATOR
Intervention: Adjuvant concurrent chemoradiotherapy (CCRT)
Number of subjects: 329
Study 36137630 — intervention group
Group type: EXPERIMENTAL
Intervention: Activity enabling uniform intervention (shorts, polo shirt, and sports shoes) provided to students, including two additional sports shirts and one pair of shorts.
Number of subjects: 24
Study 36137630 — intervention group
Group type: EXPERIMENTAL
Intervention: Activity enabling uniform intervention (shorts, polo shirt, and sports shoes).
Number of subjects: 24
Study 33028557 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardised ergonomics and posture training (10 weeks, once a week for 20-30 min)
Number of subjects: 700
Study 33028557 — intervention group
Group type: EXPERIMENTAL
Intervention: Back-fitness training (12 weeks, once a week for 45-60 min)
Number of subjects: 700
Study 36179810 — intervention group
Group type: EXPERIMENTAL
Intervention: COMT Val homozygotes group
Number of subjects: 60
Study 36179810 — intervention group
Group type: COMPARATOR
Intervention: COMT Met-carrier group
Number of subjects: 60
Study 36179810 — intervention group
Group type: COMPARATOR
Intervention: DRD2/ANKK1 and BDNF polymorphisms
Number of subjects: 60
Study 34022150 — intervention group
Group type: EXPERIMENTAL
Intervention: R-CHOP (rituximab 375 mg/m2, cyclophosphamide 750 mg/m2, doxorubicin 50 mg/m2, vincristine 1·4 mg/m2, prednisone 100 mg) every 21 days for up to six cycles
Number of subjects: 37
Study 34022150 — intervention group
Group type: EXPERIMENTAL
Intervention: R-CHOP
Number of subjects: 37
Study 32769884 — intervention group
Group type: EXPERIMENTAL
Intervention: rTMS
Number of subjects: 103
Study 32769884 — intervention group
Group type: COMPARATOR
Intervention: Control (sham rTMS)
Number of subjects: 103
Study 36476738 — intervention group
Group type: EXPERIMENTAL
Intervention: Arthroscopic rotator cuff repair without acromioplasty
Number of subjects: 86
Study 36476738 — intervention group
Group type: COMPARATOR
Intervention: Arthroscopic rotator cuff repair with acromioplasty
Number of subjects: 86
Study 34357009 — intervention group
Group type: EXPERIMENTAL
Intervention: 4000 m altitude condition
Number of subjects: 12
Study 34357009 — intervention group
Group type: EXPERIMENTAL
Intervention: 2000 m altitude condition
Number of subjects: 12
Study 34357009 — intervention group
Group type: EXPERIMENTAL
Intervention: All conditions (independent of altitude)
Number of subjects: 12
Study 36263382 — intervention group
Group type: EXPERIMENTAL
Intervention: HF-ESWT (Group A)
Number of subjects: 153
Study 36263382 — intervention group
Group type: COMPARATOR
Intervention: Control (Group B)
Number of subjects: 153
Study 34013579 — intervention group
Group type: EXPERIMENTAL
Intervention: Transitional Care Program (TCP) plus routine care
Number of subjects: 104
Study 34013579 — intervention group
Group type: COMPARATOR
Intervention: Routine care only
Number of subjects: 104
Study 34802700 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine infusion (0.5 µg/kg/h)
Number of subjects: 76
Study 34802700 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (placebo)
Number of subjects: 76
Study 34802700 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine infusion
Number of subjects: 76
Study 34496836 — intervention group
Group type: EXPERIMENTAL
Intervention: SoC + bezlotoxumab
Number of subjects: 10
Study 34496836 — intervention group
Group type: COMPARATOR
Intervention: SoC
Number of subjects: 10
Study 32118765 — intervention group
Group type: COMPARATOR
Intervention: Commercial kit (25mm penetrating length)
Number of subjects: 45
Study 32118765 — intervention group
Group type: EXPERIMENTAL
Intervention: Shorter needle (20mm penetrating length)
Number of subjects: 45
Study 34695800 — intervention group
Group type: EXPERIMENTAL
Intervention: Mass azithromycin distribution (specific dosage and duration not mentioned)
Number of subjects: 6107
Study 34695800 — intervention group
Group type: EXPERIMENTAL
Intervention: Improved latrine use by the household
Number of subjects: 6107
Study 32717058 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral D/L-3-Hydroxybutyrate
Number of subjects: 8
Study 32717058 — intervention group
Group type: COMPARATOR
Intervention: Matched intravenous D/L-3-Hydroxybutyrate
Number of subjects: 8
Study 35830550 — intervention group
Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA 100, 300, 400, or 500 U with hydrogel admixture
Number of subjects: 0
Study 35830550 — intervention group
Group type: COMPARATOR
Intervention: Placebo with hydrogel admixture
Number of subjects: 0
Study 35830550 — intervention group
Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA + hydrogel treatment groups
Number of subjects: 0
Study 35830550 — intervention group
Group type: COMPARATOR
Intervention: All groups (including placebo)
Number of subjects: 0
Study 35830550 — intervention group
Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA + hydrogel admixture
Number of subjects: 0
Study 33472353 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine
Number of subjects: 16
Study 33472353 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactic acid
Number of subjects: 16
Study 33472353 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 33472353 — intervention group
Group type: COMPARATOR
Intervention: Not sure
Number of subjects: 16
Study 35291965 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin and 5 fluorouracil (CF) followed by docetaxel (D)
Number of subjects: 116
Study 35291965 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin and 5 fluorouracil (CF) followed by docetaxel (D) + radiotherapy (RT)
Number of subjects: 116
Study 35291965 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin and 5 fluorouracil (CF)
Number of subjects: 116
Study 35508968 — intervention group
Group type: EXPERIMENTAL
Intervention: Bayesian adaptive designs
Number of subjects: 0
Study 35508968 — intervention group
Group type: EXPERIMENTAL
Intervention: Bayesian adaptive designs prioritising small sample size
Number of subjects: 0
Study 35508968 — intervention group
Group type: EXPERIMENTAL
Intervention: Bayesian adaptive designs prioritising high power
Number of subjects: 0
Study 35508968 — intervention group
Group type: EXPERIMENTAL
Intervention: Bayesian adaptive designs applied to real-world ANZ 9311 data
Number of subjects: 0
Study 32507146 — intervention group
Group type: EXPERIMENTAL
Intervention: TMJ manual therapy plus exercise therapy in addition to routine physiotherapy for neck pain (Group B)
Number of subjects: 40
Study 32507146 — intervention group
Group type: COMPARATOR
Intervention: Routine physiotherapy for neck pain (Group A)
Number of subjects: 40
Study 35393165 — intervention group
Group type: EXPERIMENTAL
Intervention: venlafaxine XR for 12 weeks
Number of subjects: 468
Study 35393165 — intervention group
Group type: EXPERIMENTAL
Intervention: augmentation with aripiprazole for 12 additional weeks
Number of subjects: 468
Study 35393165 — intervention group
Group type: COMPARATOR
Intervention: placebo for 12 additional weeks
Number of subjects: 468
Study 34269376 — intervention group
Group type: EXPERIMENTAL
Intervention: CTCA with selective FFRCT (experimental group)
Number of subjects: 1400
Study 34269376 — intervention group
Group type: COMPARATOR
Intervention: Standard clinical care pathways (standard group)
Number of subjects: 1400
Study 32108304 — intervention group
Group type: EXPERIMENTAL
Intervention: OurRelationship and ePREP interventions
Number of subjects: 742
Study 32108304 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 742
Study 33866946 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole for 6 months
Number of subjects: 102
Study 33866946 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 102
Study 34645842 — intervention group
Group type: EXPERIMENTAL
Intervention: Nocturnal oxygen therapy (NOT)
Number of subjects: 32
Study 34645842 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 34645842 — intervention group
Group type: EXPERIMENTAL
Intervention: 490 m
Number of subjects: 32
Study 35791477 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-discharge pharmacist-led follow-up (weekly for 6 months)
Number of subjects: 125
Study 35791477 — intervention group
Group type: COMPARATOR
Intervention: Routine medication guidance (control group)
Number of subjects: 125
Study 32316870 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive + Active Heat (PAH)
Number of subjects: 30
Study 32316870 — intervention group
Group type: EXPERIMENTAL
Intervention: Active Heat (AH)
Number of subjects: 30
Study 32316870 — intervention group
Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 30
Study 34290063 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer mentorship intervention (up to eight community-based self-management support sessions delivered by a peer mentor)
Number of subjects: 50
Study 34290063 — intervention group
Group type: COMPARATOR
Intervention: Usual care (information resources)
Number of subjects: 50
Study 32135488 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure therapy with Tegenaria Domestica (domestic house spider)
Number of subjects: 37
Study 32135488 — intervention group
Group type: COMPARATOR
Intervention: Control condition with Dendrobaena Veneta/Eisenaia hortensis (red earthworm)
Number of subjects: 37
Study 35116067 — intervention group
Group type: EXPERIMENTAL
Intervention: Guilingji capsules (GLJC)
Number of subjects: 96
Study 35116067 — intervention group
Group type: COMPARATOR
Intervention: Ginkgo extract tablets
Number of subjects: 96
Study 33190679 — intervention group
Group type: EXPERIMENTAL
Intervention: Levetiracetam (40 mg/kg)
Number of subjects: 286
Study 33190679 — intervention group
Group type: COMPARATOR
Intervention: Phenytoin (20 mg/kg)
Number of subjects: 286
Study 34875556 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV self-sampling kit
Number of subjects: 741
Study 34875556 — intervention group
Group type: COMPARATOR
Intervention: Written reminder
Number of subjects: 741
Study 34875556 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV positive women referred to colposcopy
Number of subjects: 741
Study 34875556 — intervention group
Group type: EXPERIMENTAL
Intervention: Histopathological confirmation
Number of subjects: 741
Study 34701328 — intervention group
Group type: EXPERIMENTAL
Intervention: TPF induction chemotherapy + cisplatin concurrent radiochemotherapy
Number of subjects: 72
Study 34701328 — intervention group
Group type: COMPARATOR
Intervention: PF adjuvant chemotherapy + cisplatin concurrent radiochemotherapy
Number of subjects: 72
Study 32105658 — intervention group
Group type: EXPERIMENTAL
Intervention: PlaqueHD toothpaste
Number of subjects: 112
Study 32105658 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 112
Study 616279865 — intervention group
Group type: EXPERIMENTAL
Intervention: NRB-Flush (non-rebreather mask with flush rate oxygen >40 L/min)
Number of subjects: 27
Study 616279865 — intervention group
Group type: COMPARATOR
Intervention: aBVM-Flush (assisted bag-valve-mask with flush rate oxygen)
Number of subjects: 27
Study 616279865 — intervention group
Group type: COMPARATOR
Intervention: NRB-Flush vs aBVM-Flush
Number of subjects: 27
Study 35568246 — intervention group
Group type: EXPERIMENTAL
Intervention: Escalated dose RT (EDRT; 70.2 Gy/39 fractions/5 days a week)
Number of subjects: 95
Study 35568246 — intervention group
Group type: COMPARATOR
Intervention: Standard dose RT (SDRT; 55.8 Gy/31 fractions/5 days a week)
Number of subjects: 95
Study 35568246 — intervention group
Group type: EXPERIMENTAL
Intervention: Escalated dose RT (EDRT)
Number of subjects: 95
Study 35568246 — intervention group
Group type: COMPARATOR
Intervention: Standard dose RT (SDRT)
Number of subjects: 95
Study 35568246 — intervention group
Group type: EXPERIMENTAL
Intervention: Both arms
Number of subjects: 95